Erika Fry

Recursion Pharmaceuticals—a relatively small company backed by the chip giant Nvidia—is betting that its massive supercomputer will give it the edge to dominate the sector.

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

We recognize some of the most staggering, game-changing, life-improving developments of the year.

The vitriol following the killing of UHC CEO Brian Thompson exposed Americans' rage about their health care system. How justified is that rage?

Tirzepatide, a drug for diabetes and obesity, has sent the 148-year-old pharma giant on a wild ride. It’s now the ninth most valuable company in the world.

Delayed prescriptions, missed payments, and bags of cash: How the hack of a UnitedHealth Group unit exposed the flaws in the health care landscape.

The research community has a lot to lose in the debate over whether the long-tailed macaque should be declared off-limits for labs.

The industry’s favorite lab monkey was already in short supply. Then the arrest of a Cambodian wildlife official made the situation a lot worse.

I was working on a feature story about a crisis in America’s lab monkey supply chain when was thrust into a medical drama myself.

In a world of fast-advancing technology and precision medicine, are our primate relatives really the best tool for developing and testing human medicines?